Um, so what evidence currently exists regarding the use of inhaled insulin in pediatric populations?

Yeah, so un- until very recently, the, uh, the use of inhaled insulin was, was off-label in, in children.

Um, but fortunately, that, that has now changed, and there is an, an FDA-approved label, and that came as a result of, uh, the Inhale1 study that we were able to complete, um, which was a randomized controlled trial, a relatively large study, uh, two hundred and thirty, uh, youth with type one diabetes primarily, although we did in- include a handful of folks with type two diabetes.

Um, a hundred and seventeen got randomized to using Technosphere or an, uh, Afrezza inhaled insulin, um, with a long-acting basal, um, and a hundred and thirteen randomized to, uh, continuing their rapid-acting analog injected insulin.

Um, importantly, the study didn't, um, include folks who were actively using insulin pump.

Um, so, so children who were on a pump had to, had to come off their pump and go back to multiple daily injections to be eligible.

Uh, and then they were treated, uh, for twenty-six weeks, um, with a primary outcome measure being, uh, change in, in hemoglobin A1C at, at that, uh, twenty-six week timeframe.

Do you mind kind of clarifying a little bit to the audience, like, why inhaled insulin has some benefits to that, you know, to that exercise scenario?